A Phase 1 Study of CBL0137 in Patients with Metastatic or Unresectable Advanced Cancer or Lymphoma
This Phase 1 study is designed to determine the best dose of CBL0137 to use when treating patients with metastatic or unresectable advanced solid tumors or lymphoma.
The study will enroll up to 48 patients from at least 2 cancer centers in the US.
In addition to other conditions for enrollment, eligible patients have cancer that has not improved or has come back after prior treatment and are otherwise in good health.
Patients who have a history of active infection, cancer involving the central nervous system, a particular EKG abnormality or other serious medical conditions may not be eligible to enroll.